Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...

Background Fabry disease (FD) is an X linked lysosomal disorder with ventricular myocardial involvement that drives morbidity and mortality. Early diagnosis of cardiac involvement can be difficult.

Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE WOODLANDS, Texas, Nov. 08, 2025 ...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., November 07, 2025--Kardigan, a heart health company modernizing cardiovascular ...

There are improved 12-month CV outcomes in patients with chronic infl-CMP following fulminant myocarditis who receive HCQ plus prednisolone.

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.

Pharmaceuticals announced that new sotagliflozin clinical data was presented at the American Heart Association, AHA, Annual ...

High-volume systemic-to-pulmonary ductal shunting occurs frequently in preterm infants and is indicated by diastolic flow reversal in the descending aorta (DAo). We studied the relationship between ...

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertensi ...

After years of searching for a therapy to combat heart failure with preserved ejection fraction, a research team may have found a breakthrough candidate. Their drug not only improved heart function in ...

Bristol Myers Squibb showcases new long-term and real-world data from cardiovascular portfolio at the AHA scientific sessions 2025: Princeton, New Jersey Wednesday, November 5, 20 ...